Filtered By:
Cancer: Prostate Cancer
Education: Study

This page shows you your search results in order of date.

Order by Relevance | Date

Total 130 results found since Jan 2013.

Where You Live Can Shape How Alzheimer ’ s Affects You
The FDA in mid-July for the first time ever approved an Alzheimer’s drug, Leqembi. The annual price-tag will run patients $26,500. The same week, the Alzheimer’s Association for the first time ever released county-level data to identify which communities are most struggling with the disease. 6.7 million Americans live with Alzheimer’s disease and 134,000 of them will die because of it each year. We’ve known these aggregate numbers for a while now, but with new data and new drugs, healthcare specialists can now better target attention and resources. [time-brightcove not-tgx=”true”] ...
Source: TIME: Health - August 7, 2023 Category: Consumer Health News Authors: Jeremy Ney Tags: Uncategorized freelance Source Type: news

Cheese consumption and multiple health outcomes: an umbrella review and updated meta-analysis of prospective studies
Adv Nutr. 2023 Jun 14:S2161-8313(23)01328-5. doi: 10.1016/j.advnut.2023.06.007. Online ahead of print.ABSTRACTThis umbrella review aims to provide a systematic and comprehensive overview of current evidence from prospective studies on the diverse health effects of cheese consumption. We searched PubMed, Embase, and Cochrane Library to identify meta-analyses/pooled analyses of prospective studies examining the associations between cheese consumption and major health outcomes from inception to August 31, 2022. We reanalyzed and updated previous meta-analyses and performed de novo meta-analyses with recently published prospec...
Source: Adv Data - June 16, 2023 Category: Epidemiology Authors: Mingjie Zhang Xiaocong Dong Zihui Huang Xue Li Yue Zhao Yingyao Wang Huilian Zhu Aiping Fang Edward L Giovannucci Source Type: research

SNHG11 ：A New Budding Star in Tumors and Inflammatory Diseases
CONCLUSION: LncRNA SNHG11 can serve as an early diagnostic biomarker, therapeutic target, and prognostic indicator in various diseases, particularly tumors. SNHG11 plays a crucial role in the occurrence and development of tumors and inflammatory diseases through various mechanisms, which has significant implications for clinical diagnosis and treatment.PMID:37165588 | DOI:10.2174/1389557523666230509122402
Source: Mini Reviews in Medicinal Chemistry - May 11, 2023 Category: Chemistry Authors: Yinxin Wu Source Type: research

Cancers, Vol. 15, Pages 2316: Review of Cardiovascular Risk of Androgen Deprivation Therapy and the Influence of Race in Men with Prostate Cancer
K. Kelly Androgen deprivation therapy is the cornerstone of prostate cancer therapy. Recent studies have revealed an association between androgen deprivation therapy and cardiovascular adverse effects such as myocardial infarction and stroke. This review summarizes the available research on the cardiovascular risk of men using androgen deprivation therapy. We also discuss racial disparities surrounding both prostate cancer and cardiovascular disease, emphasizing the importance of biological/molecular and socioeconomic factors in assessing baseline risk in patients beginning androgen ablation. Based on the literature, ...
Source: Cancers - April 15, 2023 Category: Cancer & Oncology Authors: James Fradin Felix J. Kim Grace L. Lu-Yao Eugene Storozynsky William K. Kelly Tags: Review Source Type: research

Unknown Causes of Death in Cancer Patients
CONCLUSION: Of the patients, 7.4% died of unknown causes during follow-up and the proportion of death was higher with longer follow-up and among more indolent cancers. The attribution of high percentages of unknown COD to cancer or non-cancer causes could impact population-based cancer registry studies or clinical trial outcomes with respect to measures involving CSS and mortality.PMID:37038261 | DOI:10.1097/COC.0000000000001003
Source: Clinical Prostate Cancer - April 11, 2023 Category: Cancer & Oncology Authors: Siven Chinniah Mckenzee Chiam Kyle Mani Menglu Liang Daniel M Trifiletti Daniel E Spratt Vinayak K Prasad Ming Wang Leila T Tchelebi Nicholas G Zaorsky Source Type: research

Long-term Cardiovascular Risks of Gonadotropin-releasing Hormone Agonists and Antagonists: A Population-based Cohort Study
CONCLUSIONS: GnRH antagonists may be associated with higher long-term, but not short-term, cardiovascular risks than agonists in Asian patients with PCa, particularly in those without known cardiovascular risk factors.PMID:37031076 | DOI:10.1016/j.clon.2023.03.014
Source: Clinical Prostate Cancer - April 8, 2023 Category: Cancer & Oncology Authors: J S K Chan Y H A Lee J M H Hui K Liu E C Dee K Ng P Tang G Tse C F Ng Source Type: research

ERLEADA ® (apalutamide), First-and-Only Next-Generation Androgen Receptor Inhibitor with Once-Daily, Single-Tablet Option, Now Available in the U.S.
HORSHAM, Pa., April 3, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the availability of an additional tablet strength of ERLEADA® (apalutamide) in the United States. The introduction of the 240mg tablet provides the first-and-only option for a once-daily, single-tablet Androgen Receptor Inhibitor (ARI) approved for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).With two strengths available, healthcare professionals will have the flexibility to...
Source: Johnson and Johnson - April 3, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news

Adverse cardiovascular effect following gonadotropin-releasing hormone antagonist versus GnRH agonist for prostate cancer treatment: A systematic review and meta-analysis
ConclusionGnRH antagonists appear to offer favorable safety in terms of adverse CV events and CV death compared with GnRH agonists among men diagnosed with Pca, especially those who had established CV disease at baseline.Systematic review registrationhttps://inplasy.com/inplasy-2023-2-0009/, identifier INPLASY202320009.
Source: Frontiers in Endocrinology - March 31, 2023 Category: Endocrinology Source Type: research

Cardiovascular outcomes among patients with castration-resistant prostate cancer: A comparative safety study using US administrative claims data
CONCLUSIONS: Our study sought to quantify risk of HHF, AMI and ischemic stroke among CRPC patients initiating AAP relative to ENZ within a national administrative claims database. Increased risk for HHF among AAP compared to ENZ users was observed. The difference in myocardial infarction did not attain statistical significance after controlling for residual bias, and no differences were noted in ischemic stroke between the two treatments. These findings confirm labeled warnings and precautions for AAP for HHF and contribute to the comparative real-world evidence on AAP relative to ENZ.PMID:36879362 | DOI:10.1002/pros.24510
Source: Cancer Control - March 6, 2023 Category: Cancer & Oncology Authors: Mitchell M Conover James Weaver Bo Fan Gerhard Leitz Ute Richarz Qing Li Dina Gifkins Source Type: research

Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
RARITAN, N.J., February 13, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology therapies from its robust portfolio and pipeline at the annual American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place in San Francisco on February 16-18. Building on more than a decade of leadership in the development of medicines for people diagnosed with GU cancers, Janssen will present data demonstrating its ambition to advance patient-centered treatment through precision medicine, real-world evidence a...
Source: Johnson and Johnson - February 13, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news